The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Launched by WEST CHINA HOSPITAL · May 28, 2021

Keywords

ClinConnect Summary

The PERI-STEMI trial is a clinical study that aims to compare two medications: sacubitril-valsartan and enalapril. Both drugs are used to help patients who have experienced a specific type of heart attack called ST-elevation myocardial infarction (STEMI). The main goal of this trial is to find out if sacubitril-valsartan is better at preventing changes to the heart that can happen after a heart attack, compared to enalapril.

To participate in this study, individuals must be between 18 and 75 years old and have had their first STEMI, treated with timely medical procedures within 12 hours. Participants will need to provide written consent and will be monitored throughout the trial. However, there are certain criteria that could exclude someone from joining, such as having a history of chronic heart failure or certain heart surgeries. Since the trial is not yet recruiting, more information will be available once it begins, and potential participants will be informed about what to expect during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged between 18 - 75 years old
• • First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines
• • Timely primary percutaneous coronary intervention within 12 hours from onset
• • Written informed consent acquired
• Exclusion Criteria:
• • Known history of or persistent clinical chronic heart failure prior to randomization
• • Previous use of ARNI, or intolerance or contraindications to study drugs including ARNI or ACEI
• • History of significant chronic coronary obstruction and adverse ventricular remodeling
• • History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months
• • History of hepatic impairment or history of cirrhosis with evidence of portal hypertension
• • History of chronic renal dysfunction, or eGFR \< 30 ml/min/1.73 m2
• • History of malignancy and with a life span less than one year
• • Patients with a known history of angioedema related to previous ACEIs/ARB therapy.
• • With contraindication to MRI examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed
• • Pregnancy or nursing women